Here's a quick roundup of business news for today in the OTC drug world:
Mead Johnson IPO
Mead Johnson Nutrionals, marketer of Enfamil formula, began trading today on the NYSE, spun-off by parent Bristol-Myers Squibb in an IPO. Find strategic analysis of the IPO and what it means for BMS, from our colleagues at the In Vivo Blog here. MJN raised $720 million via the IPO Tuesday, Reuters reports here. And for a look at another infant frormula business in transition, get some perspective on Wyeth's nutritionals business in the context of Pfizer's planned acquisition of the company with this story (paid content available to Tan Sheet subscribers. But you can get a free trial here.)
Sanofi Strategy
French drug maker Sanofi-Aventis is looking at small-scale acquisitions in areas including consumer health and biotech, as part of a diversification strategy, the Wall Street Journal reports here.
The In Vivo Blog take is available here.
P&G Tightens Consumer Focus
And for those who missed it last week, looks like Procter & Gamble plans to get out of the prescription drug business--but stay in OTCs. Here is the Reuters story. Look for the next issue of the Tan Sheet for more analysis.
